Target PharmaSolutions
Durham
About Target PharmaSolutions
TARGET PharmaSolutions was formed in February 2015, based on the success of HCV-TARGET, a case study of the model in Hepatitis C. Formed in 2011 by Dr. Michael Fried (University of North Carolina) and Dr. David Nelson (University of Florida), HCV-TARGET has $27 M committed to date, 6000 patients, and 50 clinical sites. The FDA has entered into a Memo of Understanding with HCV-TARGET and is an active participant on the advisory committee directing the clinical analysis. Through the utilization of this data, one sponsor has expanded their label and others have mitigated costly Phase IV commitments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $637.8K
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2016)
- Website: targetpharmasolutions.com
- Phone: (317)625-1380
Industries & Categories
Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/target-pharmasolutions-2246047 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.